Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biophytis ADR Representing 4000 Ord Shs BPTSY

Healthcare Biotechnology
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory... see more

Recent & Breaking News (OTCPK:BPTSY)

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities

Accesswire September 30, 2024

Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia

Accesswire July 22, 2024

Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity

Accesswire July 11, 2024

Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris

Accesswire July 1, 2024

Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million

Accesswire June 20, 2024

Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities

Accesswire June 19, 2024

Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens

Accesswire June 12, 2024

Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity

Accesswire June 10, 2024

Combined General Meeting of June 24, 2024

Accesswire June 7, 2024

Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Accesswire May 14, 2024

Biophytis is Deploying its Partnership Strategy in Obesity

Accesswire April 29, 2024

Biophytis Announces Transfer of ADSs to OTC Market

Accesswire April 24, 2024

Biophytis Announces Ratio Change Under its American Depositary Receipt ("ADR") Program

Accesswire April 19, 2024

Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity

Accesswire April 18, 2024

Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities

Accesswire April 8, 2024

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Accesswire April 8, 2024

Results of the Combined General Meeting on April 2, 2024

Accesswire April 4, 2024

Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia

Accesswire March 22, 2024

Biophytis Announces Receipt of Nasdaq Notice

Accesswire November 17, 2023

Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil

Accesswire October 30, 2023